FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OIVID AFFR	OVAL
OMB Number:	3235-028
Estimated average	burden
hours per response	0

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type	e Responses)																	
Name and Address of Reporting Person * Markel Stacy			2. Issuer Name and Ticker or Trading Symbol RIGEL PHARMACEUTICALS INC [RIGL]							5	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner							
(Eirst) (Middle) RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD.			3. Date of Earliest Transaction (Month/Day/Year) 03/21/2018							X_ Officer (give title below) Other (specify below) EVP Human Resources								
(Street) SOUTH SAN FRANCISCO, CA 94080			4. If Amendment, Date Original Filed(Month/Day/Year)								6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting PersonForm filed by More than One Reporting Person							
(City)		(State)	(Zip)	Table I - Non-Derivative Securities Acqui					ired, Disposed of, or Beneficially Owned									
1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Ye			Execution Date, if Code			(A) or Disposed of (Instr. 3, 4 and 5)		of (D) C	Transaction(s) Form: (Instr. 3 and 4) Direct (l			wnership orm: irect (D) : Indirect	Beneficial Ownership					
			Table II					in th a cui	is fo rrent ispos	who respond orm are not re tly valid OME red of, or Bene- vertible securi	equired to contro	to respond I number.					474 (9-02)	
1. Title of Derivative Security (Instr. 3) 2. Conversit or Exercise or Exercise of Derivative Security			3A. Deemed Execution Date, if any (Month/Day/Year)	Code		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)				9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)	Form of Derivative Security: Direct (D) or Indirect	(Instr. 4)		
				Code	v	(A)	(D)	Date Exercis	sable	Expiration Date	Title	Amous or Number of Sha	er		(Instr. 4)	(Instr. 4)	Instr. 4)	
Employee Stock Option (Right to Buy)	\$ 3.94	03/21/2018		A		125,000)	(1)	03/21/2028	Comm	1125 (000	\$ 0	125,000	D		
Report	ing Ov	vners																

		Relationships					
Reporting Owner Name / Address		Director	10% Owner	Officer	Other		
1180 VET	acy HARMACEUTICALS, INC. ERANS BLVD. SAN FRANCISCO, CA 94080			EVP Human Resources			

Signatures

/s/ Dolly Vance (Attorney-in-Fact)	03/23/2018
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) One fourth (1/4th) of the option vests one year from March 19, 2018 and thereafter the balance of the option vests in equal monthly installments over the next thirty-six (36) months.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.